Browse HDAC9

Summary
SymbolHDAC9
Namehistone deacetylase 9
Aliases KIAA0744; HDAC; MITR; HDAC7B; HD7b; HD9; HDAC7BB; HDAC9FL; HDRP; MEF-2 interacting transcription repressor ( ......
Chromosomal Location7p21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus
Domain PF12203 Glutamine rich N terminal domain of histone deacetylase 4
PF00850 Histone deacetylase domain
Function

Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Represses MEF2-dependent transcription.; FUNCTION: Isoform 3 lacks active site residues and therefore is catalytically inactive. Represses MEF2-dependent transcription by recruiting HDAC1 and/or HDAC3. Seems to inhibit skeletal myogenesis and to be involved in heart development. Protects neurons from apoptosis, both by inhibiting JUN phosphorylation by MAPK10 and by repressing JUN transcription via HDAC1 recruitment to JUN promoter.

> Gene Ontology
 
Biological Process GO:0001525 angiogenesis
GO:0001667 ameboidal-type cell migration
GO:0001975 response to amphetamine
GO:0002040 sprouting angiogenesis
GO:0002042 cell migration involved in sprouting angiogenesis
GO:0002521 leukocyte differentiation
GO:0006476 protein deacetylation
GO:0007507 heart development
GO:0007517 muscle organ development
GO:0007519 skeletal muscle tissue development
GO:0010594 regulation of endothelial cell migration
GO:0010595 positive regulation of endothelial cell migration
GO:0010631 epithelial cell migration
GO:0010632 regulation of epithelial cell migration
GO:0010634 positive regulation of epithelial cell migration
GO:0010830 regulation of myotube differentiation
GO:0014075 response to amine
GO:0014706 striated muscle tissue development
GO:0014902 myotube differentiation
GO:0014904 myotube cell development
GO:0016202 regulation of striated muscle tissue development
GO:0016570 histone modification
GO:0016575 histone deacetylation
GO:0018205 peptidyl-lysine modification
GO:0030098 lymphocyte differentiation
GO:0030183 B cell differentiation
GO:0030335 positive regulation of cell migration
GO:0032868 response to insulin
GO:0032869 cellular response to insulin stimulus
GO:0034983 peptidyl-lysine deacetylation
GO:0035601 protein deacylation
GO:0040017 positive regulation of locomotion
GO:0042113 B cell activation
GO:0042692 muscle cell differentiation
GO:0043434 response to peptide hormone
GO:0043534 blood vessel endothelial cell migration
GO:0043535 regulation of blood vessel endothelial cell migration
GO:0043536 positive regulation of blood vessel endothelial cell migration
GO:0043542 endothelial cell migration
GO:0045765 regulation of angiogenesis
GO:0045766 positive regulation of angiogenesis
GO:0048514 blood vessel morphogenesis
GO:0048634 regulation of muscle organ development
GO:0048641 regulation of skeletal muscle tissue development
GO:0048741 skeletal muscle fiber development
GO:0048742 regulation of skeletal muscle fiber development
GO:0048747 muscle fiber development
GO:0051146 striated muscle cell differentiation
GO:0051147 regulation of muscle cell differentiation
GO:0051153 regulation of striated muscle cell differentiation
GO:0051272 positive regulation of cellular component movement
GO:0055001 muscle cell development
GO:0055002 striated muscle cell development
GO:0060537 muscle tissue development
GO:0060538 skeletal muscle organ development
GO:0070932 histone H3 deacetylation
GO:0070933 histone H4 deacetylation
GO:0071375 cellular response to peptide hormone stimulus
GO:0071417 cellular response to organonitrogen compound
GO:0090049 regulation of cell migration involved in sprouting angiogenesis
GO:0090050 positive regulation of cell migration involved in sprouting angiogenesis
GO:0090130 tissue migration
GO:0090132 epithelium migration
GO:0098732 macromolecule deacylation
GO:1901342 regulation of vasculature development
GO:1901652 response to peptide
GO:1901653 cellular response to peptide
GO:1901861 regulation of muscle tissue development
GO:1903670 regulation of sprouting angiogenesis
GO:1903672 positive regulation of sprouting angiogenesis
GO:1904018 positive regulation of vasculature development
GO:2000147 positive regulation of cell motility
Molecular Function GO:0003714 transcription corepressor activity
GO:0004407 histone deacetylase activity
GO:0005080 protein kinase C binding
GO:0008134 transcription factor binding
GO:0016810 hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds
GO:0016811 hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in linear amides
GO:0017136 NAD-dependent histone deacetylase activity
GO:0019213 deacetylase activity
GO:0031078 histone deacetylase activity (H3-K14 specific)
GO:0032041 NAD-dependent histone deacetylase activity (H3-K14 specific)
GO:0033558 protein deacetylase activity
GO:0034979 NAD-dependent protein deacetylase activity
GO:0042826 histone deacetylase binding
GO:0070491 repressing transcription factor binding
Cellular Component GO:0000118 histone deacetylase complex
GO:0005667 transcription factor complex
GO:0034708 methyltransferase complex
GO:0035097 histone methyltransferase complex
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-2894862: Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
R-HSA-2644606: Constitutive Signaling by NOTCH1 PEST Domain Mutants
R-HSA-1643685: Disease
R-HSA-5663202: Diseases of signal transduction
R-HSA-2122947: NOTCH1 Intracellular Domain Regulates Transcription
R-HSA-162582: Signal Transduction
R-HSA-157118: Signaling by NOTCH
R-HSA-1980143: Signaling by NOTCH1
R-HSA-2894858: Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
R-HSA-2644602: Signaling by NOTCH1 PEST Domain Mutants in Cancer
R-HSA-2644603: Signaling by NOTCH1 in Cancer
Summary
SymbolHDAC9
Namehistone deacetylase 9
Aliases KIAA0744; HDAC; MITR; HDAC7B; HD7b; HD9; HDAC7BB; HDAC9FL; HDRP; MEF-2 interacting transcription repressor ( ......
Chromosomal Location7p21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between HDAC9 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between HDAC9 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
18829567Prostate Carcinoma; MelanomaPromote immunityPresentation of telomerase reverse transcriptase, a self-tumor antigen, is down-regulated by histone deacetylase inhibition. We found that HDAC inhibition with trichostatin A wa s associated with a decreased presentation and diminished killing of tumor cells by CTLs. Using gene array analysis, we found that HDAC inhibition resulted in a decrease of genes coding for proteasome catalytic proteins and for tapasin, an endoplasmic reticulum resident protein involved in the MHC class I pathway of endogenous antigen presentation.
23295947MelanomaInhibit immunityHDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy. Our data indicate that immunomodulation by HDACi occurs at multiple levels and their therapeutic benefit depends on the context and timing.
Summary
SymbolHDAC9
Namehistone deacetylase 9
Aliases KIAA0744; HDAC; MITR; HDAC7B; HD7b; HD9; HDAC7BB; HDAC9FL; HDRP; MEF-2 interacting transcription repressor ( ......
Chromosomal Location7p21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of HDAC9 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolHDAC9
Namehistone deacetylase 9
Aliases KIAA0744; HDAC; MITR; HDAC7B; HD7b; HD9; HDAC7BB; HDAC9FL; HDRP; MEF-2 interacting transcription repressor ( ......
Chromosomal Location7p21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of HDAC9 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0610.887
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.2440.777
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0710.922
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.2750.484
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.4740.798
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.0240.992
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.360.307
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.1590.869
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.6040.563
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.8930.239
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.3830.229
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1690.344
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of HDAC9 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277318.58.210.30.161
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275918.510.28.30.31
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211723.817.66.20.709
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.516.7-4.21
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131130.818.212.60.649
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382710.57.43.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221313.67.75.91
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.27.1-0.91
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111318.27.710.50.576
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 6116.7016.71
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 512208.311.70.515
Summary
SymbolHDAC9
Namehistone deacetylase 9
Aliases KIAA0744; HDAC; MITR; HDAC7B; HD7b; HD9; HDAC7BB; HDAC9FL; HDRP; MEF-2 interacting transcription repressor ( ......
Chromosomal Location7p21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of HDAC9. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolHDAC9
Namehistone deacetylase 9
Aliases KIAA0744; HDAC; MITR; HDAC7B; HD7b; HD9; HDAC7BB; HDAC9FL; HDRP; MEF-2 interacting transcription repressor ( ......
Chromosomal Location7p21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of HDAC9. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by HDAC9.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolHDAC9
Namehistone deacetylase 9
Aliases KIAA0744; HDAC; MITR; HDAC7B; HD7b; HD9; HDAC7BB; HDAC9FL; HDRP; MEF-2 interacting transcription repressor ( ......
Chromosomal Location7p21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of HDAC9. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolHDAC9
Namehistone deacetylase 9
Aliases KIAA0744; HDAC; MITR; HDAC7B; HD7b; HD9; HDAC7BB; HDAC9FL; HDRP; MEF-2 interacting transcription repressor ( ......
Chromosomal Location7p21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of HDAC9 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolHDAC9
Namehistone deacetylase 9
Aliases KIAA0744; HDAC; MITR; HDAC7B; HD7b; HD9; HDAC7BB; HDAC9FL; HDRP; MEF-2 interacting transcription repressor ( ......
Chromosomal Location7p21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between HDAC9 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolHDAC9
Namehistone deacetylase 9
Aliases KIAA0744; HDAC; MITR; HDAC7B; HD7b; HD9; HDAC7BB; HDAC9FL; HDRP; MEF-2 interacting transcription repressor ( ......
Chromosomal Location7p21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting HDAC9 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting HDAC9.
ID Name Drug Type Targets #Targets
DB00313Valproic AcidSmall MoleculeABAT, ACADSB, ALDH5A1, HDAC2, HDAC9, OGDH, PPARA, PPARD, PPARG, SC ......23
DB05015BelinostatSmall MoleculeHDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, H ......11
DB06603PanobinostatSmall MoleculeHDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, H ......11